Monthly Prescribing Reference

FDA Approves Simlandi, a Citrate-Free, High-Concentration, Interchangeable Biosimilar to Humira

Credit: Teva. Simlandi is an interchangeable biosimilar and can be substituted for the reference product without requiring a prescription change. The Food and Drug Administration (FDA) has approved ...
Healio

FDA approves Simlandi as third interchangeable Humira biosimilar

Please provide your email address to receive an email when new articles are posted on . Simlandi is the first interchangeable, citrate-free Humira biosimilar available in a high concentration. The ...
Nasdaq

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

PARSIPPANY, N.J. & REYKJAVÍK, Iceland--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today ...
Nasdaq

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership ...
JD Supra

Teva and Alvotech Announce Launch of SIMLANDI (adalimumab-ryvk) Injection in the U.S.

On May 20, 2024, Teva Pharmaceuticals (“Teva”) and Alvotech announced the availability of SIMLANDI (adalimumab-ryvk) injection in the United States, for the treatment of adult rheumatoid arthritis, ...